Huisheng Bio's GLP-1R/GCGR dual-target agonist P052 injection, a subsidiary of Sihuan Pharmaceutical, was approved for IND for type 2 diabetes and obesity.Recently, Huisheng Biologics, a subsidiary of Sihuan Pharmaceutical, announced that its GLP-1R/GCGR dual-target agonist P052 injection has been a
2025-09-19 healthy